Alex Gorsky, chairman and CEO of Johnson & Johnson, said it would be inappropriate to speculate on when Emergent Biosolutions will be authorized to manufacture the company’s Covid-19 vaccine, but he is confident it will happen soon.
“We’re actively working with regulators as we speak. I think that we’ve had a great partnership with them throughout this process and it would be inappropriate for me to speculate” on pinpointing a date or time, Gorsky said during the Wall Street Journal Tech Health Event on Wednesday. He added that he was “confident that we will be able to get that status in the near future.”
Testifying before the House Select Subcommittee on the Coronavirus crisis last month, Emergent CEO Bob Kramer said the he expected the plant to resume production of the Johnson & Johnson Covid-19 vaccine drug substance “within a matter of days.”
Some background: Emergent stopped manufacturing the vaccine substance after an inspection found there was cross contamination between the J&J vaccine and the AstraZeneca vaccine the facility was making at the same time. Emergent has since stopped making the AstraZeneca vaccine substance at its Baltimore facility.
The FDA had also been evaluating over 100 million doses of the J&J vaccine Emergent manufactured, which be made available to the public if production is authorized.